FAQ
Is there a minimum patient number, which should be included into the trial?
- Yes, a minimum of 20 patients should be recruited per centre.
How long is the study period?
- Study period is (5-)7 days within a self-selected week until August 30th 2020.
Which patients should be included?
- All patients that match the inclusion/exclusion criteria with planned surgery within study week should be included in the trial (consecutive numbering!). Furthermore, each centre should record how many patients were screened and how many failed/met the different eligibility criteria
What about patients admitted and undergoing surgery during night?
- Patients admitted to the hospital during night and undergoing immediate surgery are not included in the study.
Who is performing the blood test to evaluate cause of anaemia?
- The hospital or any other system that works for you is responsible for performing the blood test.
Who is paying for the anaemia management?
- We do not have any funding to provide compensation. However, hospitals without BUT INTEREST in routine anaemia management should participate in this (5-)7 days prevalence trial because of the following advantages:
- to estimate the number of patients with iron/folate acid/vitamin B12 deficiency and anaemia of chronic kidney disease/inflammation
- to find out which patient group would benefit from treatment and how to set up an anaemia management
- to get a hint about costs
Which patients should be excluded?
- Patients with preoperative autologous blood donation
- Patients with planned revision surgery within the study period
- Patients whose first surgery during hospitalisation was before the start of the study period (the first surgery during hospitalisation must be within the study week)
This website uses cookies. By continuing the use of the website you agree with the use of cookies. OKPrivacy policy